Merck & Co., Inc. (MRK) Stock Forecast & Price Target

$109.73

+0.33 (+0.30%)

(As of 10/11/2024 ET)

Merck & Co., Inc. - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
1

Hold
2

Buy
12

Based on 15 Wall Street analysts who have issued ratings for Merck & Co., Inc. in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, 2 have given a hold rating, 9 have given a buy rating, and 3 have given a strong buy rating for MRK.

Consensus Price Target

$133.00
21.21% Upside

According to the 15 analysts' twelve-month price targets for Merck & Co., Inc., the average price target is $133.00. The highest price target for MRK is $155.00, while the lowest price target for MRK is $104.00. The average price target represents a forecasted upside of 21.21% from the current price of $109.73.

Get the Latest News and Ratings for MRK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Merck & Co., Inc. and its competitors.

MRK Analyst Ratings Over Time

Type	Current Forecast 10/13/23 to 10/12/24	1 Month Ago 9/13/23 to 9/12/24	3 Months Ago 7/15/23 to 7/14/24	1 Year Ago 10/13/22 to 10/13/23
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	14 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$133.00	$134.58	$134.33	$124.68
Forecasted Upside	21.21% Upside	16.78% Upside	5.15% Upside	19.88% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Musk’s new company could top a trillion? (Ad)

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.

MRK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Merck & Co., Inc. Stock vs. The Competition

Type	Merck & Co., Inc.	Medical Companies	S&P 500
Consensus Rating Score	2.93	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	21.23% Upside	10,374.29% Upside	6.83% Upside
News Sentiment Rating	Neutral News See Recent MRK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/9/2024	UBS Group 4 of 5 stars		Lower Target	Buy ➝ Buy	$142.00 ➝ $136.00	+23.32%
10/9/2024	Truist Financial 2 of 5 stars		Lower Target	Buy ➝ Buy	$143.00 ➝ $132.00	+20.61%
10/7/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$142.00 ➝ $140.00	+28.83%
10/3/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$155.00 ➝ $155.00	+39.53%
7/31/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$150.00 ➝ $145.00	+29.13%
Get the Latest News and Ratings for MRK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$140.00 ➝ $125.00	+9.83%
7/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$132.00 ➝ $134.00	+4.92%
6/5/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$140.00 ➝ $143.00	+11.73%
3/11/2024	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Sell	$104.00	-15.33%
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$125.00 ➝ $135.00	+17.63%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$115.00	+10.15%
10/27/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$132.00	+25.04%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$123.00	+15.70%
4/16/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
4/13/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$105.00 ➝ $130.00	+14.29%
4/11/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$123.00 ➝ $124.00	+10.11%
4/10/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mara Goldstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$130.00	+15.44%
3/7/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$122.00 ➝ $127.00	+14.14%
3/7/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$125.00 ➝ $126.00	+13.24%
3/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$125.00	+16.95%
2/23/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$120.00 ➝ $125.00	+13.08%
2/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$120.00 ➝ $122.00	+17.92%
1/3/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$108.00 ➝ $120.00	+8.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:24 PM ET.

Should I Buy Merck & Co., Inc. Stock? MRK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 6, 2024. Please send any questions or comments about these Merck & Co., Inc. pros and cons to contact@marketbeat.com.

Merck & Co., Inc.
Bull Case

Here are some ways that investors could benefit from investing in Merck:

Merck's stock price is currently at $113.71, which may present a buying opportunity for investors looking for value.
Merck has a strong average rating of "Buy" from analysts, indicating positive sentiment towards the company's performance.
Recent analyst forecasts suggest potential growth in Merck's earnings per share, which could attract investors seeking profitability.
Merck's market cap of $288.01 billion reflects the company's significant size and stability in the market.
Merck's diverse portfolio of pharmaceutical products provides a wide range of revenue streams, reducing dependency on a single product.

Merck & Co., Inc.
Bear Case

Investors should be bearish about investing in Merck for these reasons:

Merck's stock has experienced a decline from its 1-year high of $134.63, indicating potential volatility in the market.
Some analysts have issued a sell rating on Merck's stock, suggesting caution in the company's performance outlook.
Merck's price-to-earnings ratio of 126.34 may be considered high by some investors, indicating a premium valuation.
The company's debt-to-equity ratio of 0.80 may raise concerns about its financial leverage and risk exposure.
Merck's recent decrease in trading volume compared to its average volume could signal reduced investor interest or activity.

MRK Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Merck & Co., Inc. is $133.00, with a high forecast of $155.00 and a low forecast of $104.00.
: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There is currently 1 sell rating, 2 hold ratings, 9 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRK shares.
: According to analysts, Merck & Co., Inc.'s stock has a predicted upside of 21.21% based on their 12-month stock forecasts.
: Over the previous 90 days, Merck & Co., Inc.'s stock had 2 upgrades by analysts.
: Merck & Co., Inc. has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, Evercore ISI, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Merck & Co., Inc. more than other "medical" companies. The consensus rating score for Merck & Co., Inc. is 2.93 while the average consensus rating score for "medical" companies is 2.79. Learn more on how MRK compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

This page (NYSE:MRK) was last updated on 10/12/2024 by MarketBeat.com Staff

From Our Partners